Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 16/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.48 |
| ▸ | SAE1 | Q9UBE0 | 2/20 | 0.48 |
| ▸ | UBA2 | Q9UBT2 | 2/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | BCR | P11274 | 1/20 | 0.47 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.47 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1134936 | 0.83 | JAK1 (0.42) | — | |
| SCHEMBL1135047 | 0.82 | JAK2 (0.44) | — | |
| SCHEMBL1134973 | 0.82 | JAK2 (0.46) | — | |
| SCHEMBL1134939 | 0.81 | JAK2 (0.41) | — | |
| SCHEMBL1134944 | 0.80 | JAK1 (0.43) | KDM4E | |
| SCHEMBL1134917 | 0.80 | KMT2A (0.49) | MAPTKDM4EPOLBNPC1HTT | |
| SCHEMBL1134977 | 0.80 | JAK2 (0.44) | NPC1 | |
| SCHEMBL13708193 | 0.75 | MAPT (0.64) | MAPTKDM4ESAE1UBA2MITF | |
| SCHEMBL5819066 | 0.75 | KDR (0.51) | MAPTKDM4ESAE1UBA2MITF | |
| SCHEMBL17208650 | 0.74 | MAPT (0.56) | MAPTKDM4ESAE1UBA2MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027123-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-02-23 | — | — | EP | claimed |
| US-7846923-B2 | Compounds and compositions as protein kinase inhbitors | IRM LLC (BM) | 2010-12-07 | — | — | US | claimed |
| US-20100048552-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2010-02-25 | — | — | US | claimed |
| EP-2027123-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-02-23 | — | — | EP | disclosed |
| EP-2027123-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-02-23 | — | — | EP | disclosed |
| US-7846923-B2 | Compounds and compositions as protein kinase inhbitors | IRM LLC (BM) | 2010-12-07 | — | — | US | disclosed |
| US-7846923-B2 | Compounds and compositions as protein kinase inhbitors | IRM LLC (BM) | 2010-12-07 | — | — | US | disclosed |
| US-7846923-B2 | Compounds and compositions as protein kinase inhbitors | IRM LLC (BM) | 2010-12-07 | — | — | US | disclosed |
| US-20100048552-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2010-02-25 | — | — | US | disclosed |
| US-20100048552-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2010-02-25 | — | — | US | disclosed |
| US-20100048552-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2010-02-25 | — | — | US | disclosed |
| WO-2007134259-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048552-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS | BMX, FYN, FRK | MAPT 2536/4885KDM4E 2829/4885SAE1 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.